Kaleido Biosciences, Inc.
KLDO
$0.002
$0.00191,900.00%
OTC PK
| 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | |
|---|---|---|---|---|---|
| Revenue | 1.10M | 855.00K | 1.23M | 1.27M | 975.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.10M | 855.00K | 1.23M | 1.27M | 975.00K |
| Cost of Revenue | 67.80M | 66.57M | 64.82M | 60.02M | 55.97M |
| Gross Profit | -66.70M | -65.71M | -63.58M | -58.74M | -54.99M |
| SG&A Expenses | 20.97M | 21.56M | 23.65M | 23.43M | 23.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -145.00K | 193.00K | 193.00K | 193.00K | 193.00K |
| Total Operating Expenses | 88.63M | 88.32M | 88.66M | 83.63M | 80.04M |
| Operating Income | -87.52M | -87.46M | -87.43M | -82.36M | -79.07M |
| Income Before Tax | -90.29M | -90.03M | -90.08M | -85.11M | -81.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.29 | -90.03 | -90.08 | -85.11 | -81.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.29M | -90.03M | -90.08M | -85.11M | -81.62M |
| EBIT | -87.52M | -87.46M | -87.43M | -82.36M | -79.07M |
| EBITDA | -85.16M | -85.14M | -85.25M | -80.33M | -77.24M |
| EPS Basic | -2.16 | -2.24 | -2.35 | -2.38 | -2.44 |
| Normalized Basic EPS | -1.35 | -1.40 | -1.47 | -1.49 | -1.53 |
| EPS Diluted | -2.16 | -2.24 | -2.35 | -2.38 | -2.44 |
| Normalized Diluted EPS | -1.35 | -1.40 | -1.47 | -1.49 | -1.53 |
| Average Basic Shares Outstanding | 167.41M | 160.79M | 153.77M | 143.11M | 133.75M |
| Average Diluted Shares Outstanding | 167.41M | 160.79M | 153.77M | 143.11M | 133.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |